Company dossier
Mankind Pharma
NSE:MANKIND · ISIN INE634S01028
- Close
- Unavailable Date unavailable
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Mankind Pharma
Financials
Structured filings
Exchange XBRLReported financial periods
| Metric | Quarter · FY26 · 31 Mar 26 | FY26 · 31 Dec 25 | Half year · FY26 · 30 Sept 25 | Quarter · FY26 · 30 Jun 25 | FY25 · 31 Mar 25 | Quarter · 31 Dec 24 |
|---|---|---|---|---|---|---|
| Revenue | ₹3,442.9 Cr | ₹3,567.2 Cr | ₹3,697.2 Cr | N/A | N/A | ₹3,230 Cr |
| Profit before tax | ₹656.2 Cr | ₹505.8 Cr | ₹621.7 Cr | N/A | N/A | ₹493.9 Cr |
| Profit after tax | ₹559.4 Cr | ₹413.9 Cr | ₹520.2 Cr | N/A | N/A | ₹384.5 Cr |
| Finance cost | ₹141.8 Cr | ₹157.2 Cr | ₹169.7 Cr | N/A | N/A | ₹238.9 Cr |
| Impairment | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS | ₹13.44 | ₹9.90 | ₹12.39 | N/A | N/A | ₹9.45 |
Accounting lens
Research frameworkWhat deserves analyst attention
Confirm quarterly, year-to-date and annual periods before calculating growth. The table preserves the exchange period labels.
Treat scope changes as breaks in comparability and open the linked XBRL before relying on a trend.
Sector metrics and accounting choices require additional facts beyond this common cross-company layer.